background & aim: sexual health is an essential element of quality of life, affecting both physical and psychological domains. hormones used in contraceptive methods have contradictory effects on sexual function. in this study, we aimed to compare sexual function in women using combined oral contraceptives (coc) and depot medroxyprogesterone acetate (dmpa), referred to healthcare centers affili...

Background Increasing evidence suggests depot medroxyprogesterone acetate (DMPA) and intravaginal practices may be associated with human immunodeficiency virus (HIV-1) infection risk; however, the mechanisms are not fully understood. This study evaluated the effect of DMPA and intravaginal practices on the genital proteome and microbiome to gain mechanistic insights. Methods Cervicovaginal se...

2. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesterone acetate. Contraception. 2006;73:577-83. Abstract: INTRODUCTION: Depot medroxyprogesterone acetate (DMPA) suppresses pituitary gonadotrophin output, thus, suppressing ovulation. Estrogen production from the ovary is also strongly inhibited, and the resulting estrogen deficiency has a detrimental impact on b...

1. What exactly are injectable contraceptives, specifically DMPA and NET-EN? DMPA, or depot medroxyprogesterone acetate, and NET-EN, short for norethisterone enanthate, are contraceptives that contain a kind of hormone called progestin. Both are given by injection. DMPA (widely known by its marketed name Depo-Provera) is administered every three months, while NET-EN (or Noristerat) is given eve...

Depot medroxyprogesterone acetate (DMPA) is a commonly used form of contraception, with noncontraceptive benefits for the user. The mode of action is through the suppression of ovulation. It leads to hypoestrogenism which causes dryness of the vagina and dyspareunia. We present in this paper a patient that was very symptomatic with regard to vaginal atrophic changes determined by vaginal cytolo...

High discontinuation rates for depot medroxyprogesterone acetate (DMPA) in adolescents may contribute to the number of unintended pregnancies. Many cite vaginal bleeding as a reason for discontinuing DMPA use. In this study, we attempted to determine if treating DMPA-associated vaginal bleeding with monophasic oral contraceptive pills (OCP) raised continuation rates. A total of 131 patients who...

Background In 2004, WHO Pharmaceuticals Newsletter reported a Pfizer Canada advice originated by results of new clinical studies that suggest the association between use of medroxyprogesterone acetate suspension for injection and substantial loss in bone mineral density. The publication stressed: “The loss in bone density is greater with increasing duration of treatment. The loss in bone densit...

The purpose of this Position Paper is to review the published Black Box Warning regarding depot medroxyprogesterone acetate (DMPA) and bone loss as it relates to adolescent girls. The scientific findings that prompted the Food and Drug Administration to issue the warning are reviewed and the following additional issues are considered: (1) likely low risk of fracture related to DMPA use, (2) evi...

We thank Dr Curry for an accurate summary of our study entitled ‘Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture’. Nevertheless, we do not recommend more selective use of depot medroxyprogesterone acetate (DMPA) on account of fracture risk, as we believe that this recommendation would reduce access to an effective, safe contraceptive without actually reduci...

This paper describes experiments designed to test the effect of depot medroxyprogesterone acetate (DMPA) on calcium metabolism of adult ovariectomized rats. The 24 animals were randomly assigned to control or treated groups. Treated rats received 15 mg of DMPA i.m. per week, during four or twelve weeks. Controls received solvent alone. The variables characterizing the metabolism of Ca (daily ra...